April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs
Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.
You may also be interested in...
Could The US FDA Set Clinical Trial Diversity Minimums?
Oncology Center of Excellence Director Richard Pazdur asked whether the FDA should have more conversations with sponsors about site selection and percentages of US participants.
Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1
The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.